Regeneron Pharmaceuticals, Inc. — Q3 2023 Form 10-Q Summary
Business context and reporting period
Regeneron is an integrated biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious diseases. The filing covers the three and nine months ended September 30, 2023, compared with the corresponding 2022 periods.
Key commercial products include EYLEA, newly approved EYLEA HD, Libtayo, and products commercialized with Sanofi and Bayer, including Dupixent, Kevzara, and ex-U.S. EYLEA.
Financial performance and position
| Metric | Q3 2023 | Q3 2022 | Change |
|---|---|---|---|
| Revenue | $3,362.7 million | $2,936.2 million | +14.5% |
| Income from operations | $1,111.0 million | $1,223.7 million | -9.2% |
| Operating margin | 33.0% | 41.7% | Down 8.7 points |
| Net income | $1,007.8 million | $1,315.7 million | -23.4% |
| Diluted EPS | $8.89 | $11.66 | -23.8% |
| Net margin | 30.0% | 44.8% | Down 14.8 points |
| Metric | Nine months 2023 | Nine months 2022 | Change |
|---|---|---|---|
| Revenue | $9,682.9 million | $8,758.5 million | +10.6% |
| Income from operations | $3,074.2 million | $3,592.1 million | -14.4% |
| Operating margin | 31.7% | 41.0% | Down 9.3 points |
| Net income | $2,794.0 million | $3,141.3 million | -11.1% |
| Diluted EPS | $24.57 | $27.73 | -11.4% |
Revenue and operating drivers
- Q3 net product sales were $1,786.1 million, down slightly from $1,801.4 million. Nine-month net product sales were $5,226.2 million, up from $5,194.4 million.
- U.S. EYLEA sales declined 11% in Q3 and 8% year to date, primarily because of lower net selling prices and increased competition. EYLEA HD contributed $42.7 million in U.S. sales during Q3 and the first nine months.
- Collaboration revenue increased to $1,438.3 million in Q3 from $1,050.6 million, driven primarily by higher Sanofi collaboration revenue. Nine-month collaboration revenue was $4,133.1 million versus $3,326.7 million.
- Sanofi collaboration revenue included $863.0 million of Regeneron's share of antibody-collaboration profits and a final $50.0 million sales milestone in Q3. Bayer collaboration revenue was $377.1 million in Q3.
- Operating expenses increased 31.5% in Q3 and 27.9% year to date. Research and development increased to $1,075.3 million in Q3, while SG&A increased to $640.5 million.
- Q3 included a $100.0 million acquired in-process research and development charge for an Alnylam ALN-APP development milestone. Nine-month acquired IPR&D also included a $45.0 million Sonoma upfront payment.
- Other income was affected by $100.3 million of net unrealized losses on equity securities in Q3 and $295.9 million year to date. Higher interest income partly offset investment losses.
- Effective tax rates were 9.3% in Q3 and 8.4% for the first nine months, compared with 12.9% and 11.1%, respectively, in the prior-year periods.
Cash flow, liquidity, debt, and capital allocation
- Operating cash flow was $3,504.3 million for the first nine months, compared with $3,295.0 million in 2022.
- Investing cash flow was negative $3,118.9 million, including $467.2 million of capital expenditures, $145.7 million of contingent consideration payments for Libtayo rights, and $51.1 million related to the Decibel acquisition.
- Financing cash flow was negative $1,344.0 million, including $1,946.0 million of share repurchases and $844.5 million of proceeds from common-stock issuances.
- Cash and cash equivalents were $2,152.3 million at September 30, 2023, compared with $3,105.9 million at year-end 2022. Total marketable securities were $13,539.8 million, resulting in cash and marketable securities of approximately $15.7 billion.
- Working capital was $15,036.2 million. Long-term debt was $1,982.6 million and finance lease liabilities were $720.0 million; total indebtedness was approximately $2.703 billion.
- The company had $750.0 million available under its revolving credit facility.
- Capital expenditures are expected to be $660 million to $700 million for full-year 2023, primarily for Tarrytown and Rensselaer campus and manufacturing expansion.
- Regeneron repurchased 2.6 million shares for $1,923.8 million during the first nine months. The January 2023 authorization had $1.826 billion remaining at September 30.
Material changes, outlook, and unusual items
- FDA approved EYLEA HD in August 2023 for wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy after a June complete response letter related to third-party manufacturing inspection observations.
- Regeneron completed its acquisition of Decibel in September 2023 for $101.3 million in cash and recorded a $43.7 million contingent value-right liability. Potential additional CVR payments could total approximately $97 million.
- An expanded BARDA agreement could provide up to approximately $326 million to support development, manufacturing, and licensure of a next-generation COVID-19 antibody. The company recognized $34.2 million of related revenue in Q3.
- Dupixent continued to generate strong collaboration economics, but the company received an FDA complete response letter in October 2023 for the chronic spontaneous urticaria application because additional efficacy data were required.
- Management reported positive Phase 3 COPD data for Dupixent and expected an interim analysis of a replicate study later in 2023. The filing does not provide a formal revenue or earnings outlook.
- Regeneron discontinued enrollment in the full-dose Libtayo combination cohort of REGN5678 after observing two immune-mediated Grade 5 adverse events. Monotherapy and lower-dose combination strategies are being evaluated.
- Key anticipated regulatory events include decisions for odronextamab, linvoseltamab, EYLEA HD in the EU and Japan, and other pipeline programs; timing remains subject to regulatory review and clinical results.
Principal risks and contingencies
- EYLEA and EYLEA HD are strategically important. EYLEA U.S. regulatory exclusivity expires after May 17, 2024, and biosimilar competition may pressure pricing and volume.
- The company faces significant competition across ophthalmology, immunology, oncology, and other therapeutic areas, as well as risks relating to reimbursement, drug-price controls, and Medicare negotiation provisions.
- Manufacturing capacity and third-party fill/finish performance remain material risks. The EYLEA HD approval delay demonstrates the potential effect of contract-manufacturer inspection findings.
- Pending patent proceedings involving EYLEA, EYLEA pre-filled syringe, Praluent, and REGEN-COV could affect commercialization, market exclusivity, or financial results.
- The company faces DOJ, False Claims Act, anti-kickback, patient-assistance, payor, and related investigations and litigation. Accrued legal contingencies were not material, but certain possible losses were not estimable.
- Results depend substantially on collaborations with Sanofi and Bayer. Termination, breach, or underperformance by either collaborator could materially affect revenue and commercialization capabilities.
- Clinical, regulatory, safety, supply-chain, data privacy, cybersecurity, foreign-exchange, tax, and acquisition-integration risks could materially affect future performance.
Most important facts for investors to verify
- Whether EYLEA HD adoption offsets declining U.S. EYLEA pricing and upcoming biosimilar competition.
- The sustainability of Dupixent-driven Sanofi collaboration profits after development-cost reimbursements and milestone payments.
- Progress and regulatory outcomes for Dupixent COPD and chronic spontaneous urticaria, odronextamab, linvoseltamab, and other late-stage programs.
- Resolution and potential financial exposure from EYLEA patent litigation, DOJ and False Claims Act matters, and other healthcare-pricing investigations.
- Execution of manufacturing expansion and the ability of internal and third-party facilities to support EYLEA HD and pipeline demand.
- Future capital expenditures, share repurchases, acquisition-related payments, and the company’s ability to maintain substantial liquidity despite declining cash balances.